Circio Holding (”Circio” or ”the Company”) announced, on the 30th of January 2026, the final outcome of the rights issue, which attracted subscriptions of approx. NOK 77.9m, corresponding to a subscription of 156% relative to the targeted NOK 50m. As approved by the extraordinary general meeting on the 12th of January 2026, Circio will also carry out a parallel private placement of approx. NOK 15m to accommodate oversubscription of the rights issue. This brings total gross proceeds from the transactions to approx. NOK 65m, compared with the initially targeted NOK 50m. The capital injection from the rights issue and the parallel private placement is estimated to provide a cash runway until Q1-27. Including the potential exercise of the attached warrants in Q2-26, Circio is estimated to have sufficient capital to fund operations into early Q1-28.
Analyst Group’s View of the Outcome
Financing impact
The oversubscribed rights issue, with strong support from both existing and new shareholders, as well as from the board and management (who subscribed for NOK 1.8m), reflects confidence in the technological progress achieved to date, the associated partnership with a major pharmaceutical company, and the solid pipeline of upcoming development milestones in 2026. With gross proceeds of approx. NOK 65m, we estimate that Circio has a cash runway until Q1-27.
Moreover, the attached 1:1 warrants, exercisable in Q2-26, represent a source of potential upside to Circio’s funding profile. With the warrant terms set at a strike price equivalent to a 20% discount to the VWAP during 8–22 May 2026, Circio could raise up to an additional NOK 52m in gross proceeds, assuming a share price in line with the subscription price of the rights issue (NOK 1.0 per share), or approx. NOK 106m given our Base scenario, assuming a share price of NOK 2.03 per share. In a scenario where the share price develops more favorably ahead of the warrant exercise window, driven by upcoming preclinical data readouts and continued platform progress, this would provide further upside to the estimated cash runway. Assuming full warrant exercise under the more conservative pricing scenario, and estimating a somewhat elevated burn rate going forward (approx. NOK -4.5m per month), primarily driven by higher R&D spend as the platform advances, we estimate that the net proceeds from the warrants could extend the cash runway into Q1-28.
Operational and value-creation implications
With the extended runway, Circio is financially positioned to accelerate the circVec R&D activities and strengthen the scientific team in Stockholm, which will be crucial to progress several value-de-risking preclinical milestones across the circVec platform. In the near term (H1-26), we expect readouts from circVec 4.0 in vivo proof-of-concept studies in heart, eye and CNS, which should provide early validation of next-generation construct performance across multiple tissues and further inform target and construct selection.
Moreover, key subsequent milestones include the generation of in vivo CNS PoC data linked to the ongoing partnership with a major pharmaceutical company, as well as disease-model efficacy data in eye and heart indications, which is expected in H2-26, something that would further support the translational relevance of circVec and strengthen partner confidence in AAV-based gene therapy applications.
Within cell therapy, active T-cell targeting data expected in Q2-26, together with continued third-party validation of the broader in vivo cell therapy field, driven by ongoing industry readouts, are expected to reduce perceived modality risk over time and expand the platform’s strategic optionality. Collectively, we view these milestones as important steps in further de-risking the platform and increasing its attractiveness in future partnering discussions, supported by the funding secured through the oversubscribed rights issue. If these milestones are achieved with positive outcomes, they would, all else being equal, contribute to further de-risking of the platform and increase the probability of securing licensing partnerships, supporting revised valuation scenarios.
Conclusion
In summary, Analyst Group believes that the oversubscribed rights issue meaningfully improves Circio’s financial position and enables continued execution on the Company’s preclinical development strategy. With funding estimated into Q1-28, based on a conservative assumption of warrant exercise in Q2-26 at a strike price derived from the rights issue subscription price (NOK 1.0 per share), the Company is well positioned to fund the upcoming acceleration of circVec R&D activities and strengthen the scientific team in Stockholm. With key de-risking events such as active T-cell targeting data expected in Q2-26, as well as the generation of in vivo CNS PoC data linked to the ongoing partnership with a major pharmaceutical company and disease-model efficacy data in eye and heart indications expected in H2-26, Circio has a pipeline of upcoming value-inflecting milestones that could act as catalysts for increased licensing partner interest and the valuation of the Company.
